Attachment 7.7-C

Page 1

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and Prevention of COVID

_	<u>X</u>	The states assures coverage of CO	VID-19 treatment,	including specialized	equipment and	therapies
(inc	luding preventive therapies).				

X The state assures that such coverage:

- 1. Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
- Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
- 3. Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19;
- 4. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 5. Is provided to the optional COVID-19 group, if applicable; and
- 6. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

X Applies to the state's approved Alternative Benefit Plans, without any deduction,
cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

_	X The state assures compliance with the HHS COVID-19 PREP Act declarations and					
ā	uthorizations, including all of the amendments to the declaration.					
Addition	Additional Information (Optional):					
_						
L						

TN: <u>22-0015</u> Approval Date: _____

Supersedes TN: New Effective Date: March 11, 2021

Attachment 7.7-C

Page 2

Coverage for a Condition that May Seriously Complicate the Treatment of COVID

X The states assures coverage of treatment for a condition that may seriously complicate the	
treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to h	iave
COVID-19.	

- X The state assures that such coverage:
 - 1. Includes items and services, including drugs, that were covered by the state as of March 11, 2021;
 - 2. Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;
 - 3. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
 - 4. Is provided to the optional COVID-19 group, if applicable; and
 - 5. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
 - X Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
- X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

,	Additional Information (Optional):			

Reimbursement

 \underline{X} The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

TN: <u>22-0015</u> Approval Date: _____

Supersedes TN: New Effective Date: March 11, 2021

Attachment 4.19-B Page 1 addresses Outpatient Hospital Services; reimbursement is based on a fee for service and may not exceed the amount established for any qualified provider for the same service. Other services specific to hospitals may not exceed the established Medicare upper limits based on reasonable cost.

Pages 2, 2a and 2b address Federally Qualified Health Center and Rural Health Center payment methodology; all Federally Qualified Health Centers and Rural Health Clinics are reimbursed on a prospective payment system. Covered Core Services are discussed on page 2a, include Physician services specified in 42 CFR 405.2412 as well as nurse practitioner or physician assistant services specified in 42 CFR 405.2414. Page 2d specifies that where a center/clinic furnishes services through a managed care organization, BMS will make a supplemental payment to the extent required by the Act.

Pages 3a and 3aa address payment methodology for Physicians' Services, while Page 3b discusses supplemental payments for certain Physician Services.

Pages 5 and 14 discuss payment methodology for different provider specialties for Nurse Practitioner services. Page 6 discusses payment for services provided by established clinics; payments are not to exceed that allowed for the services when provided by other qualified providers.

Page 7 includes payments for physical and occupational therapy. Pages 8 and 9 include payment methodologies for prescribed drugs. Page 13 discusses payment for respirator care services.

TN: <u>22-0015</u> Approval Date: _____

Supersedes TN: New Effective Date: March 11, 2021

Supersedes TN: New

	Attachmen	
	is establishing rates or fee schedule for COVID-19 treatment, including specialized d therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and	Page 3
	The state's rates or fee schedule is the same for all governmental and private providers.	
	The below listed providers are paid differently from the above rate schedule payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:	s and
Additional Info	ormation (Optional):	
kept private to the constance of the con	e Statement Under the Privacy Act of 1974 any personally identifying information obtained whe extent of the law. An agency may not conduct or sponsor, and a person is not required to a of information unless it displays a currently valid Office of Management and Budget (OMB) of MB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of formation requirements under this control number is estimated to take up to 1 hour per response regarding this burden estimate or any other aspect of this collection of information, including reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reporter, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.	respond control f the use.
ΓN: <u>22-0015</u>	Approval Date:	

Effective Date: March 11, 2021